Bayer’s Promising Parkinson’s Study: AAV2-GDNF Gene Therapy in Focus

Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.

Study Overview: Bayer AG, in collaboration with AskBio Inc, is conducting a Phase 2 clinical study titled ‘A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson’s Disease.’ The study aims to assess the safety and efficacy of AAV2-GDNF gene therapy in treating moderate Parkinson’s Disease, a significant step in addressing this debilitating condition.

Intervention/Treatment: The study tests AAV2-GDNF, a gene therapy delivered through bilateral image-guided infusion into the putamen, against a control surgery involving partial burr/twist holes without dural penetration. This intervention seeks to improve motor function in Parkinson’s patients.

Study Design: This interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused, aiming to provide new therapeutic insights.

Study Timeline: The study began on June 11, 2024, with an estimated completion date yet to be announced. The latest update was submitted on June 30, 2025, indicating ongoing recruitment and progress.

Market Implications: This study could significantly impact Bayer’s stock performance by potentially introducing a novel treatment for Parkinson’s Disease, enhancing investor confidence. Given the competitive landscape in neurodegenerative disease therapies, successful outcomes could position Bayer favorably against competitors.

The study is ongoing, with further details available on the ClinicalTrials portal.